Novartis AG ADR
NVS: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$997.00 | Jcfrf | Ntmxgcn |
Novartis Holds a Strong Portfolio of Branded Drugs and a Robust Pipeline Supporting a Wide Moat
Business Strategy and Outlook
With strong positions in multiple key therapeutic areas, Novartis is well positioned for steady long-term cash flows. Strong intellectual property supporting multibillion-dollar products, combined with an abundance of late-pipeline products, creates a wide economic moat. While patent losses on multiple sclerosis drug Gilenya and cancer drug Afinitor will weigh on near-term growth, a strong portfolio of drugs along with a robust pipeline should ensure steady long-term growth.